PTC Therapeutics, Inc. (PTCT) Financial Statements
PTC Therapeutics, Inc. (PTCT) reported trailing twelve-month revenue of $1.0B (down 42.8% year on year) and net income of -$38.4M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$39.8M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
PTCTPTC Therapeutics, Inc.Follow PTCT — free
—
Price chart with a free account
- Market cap
- 5.1B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.03 | 0.03 | 0.04 | 0.08 | 0.19 | 0.26 | 0.31 | 0.38 | 0.54 | 0.70 | 0.94 | 0.81 | 1.73 | 1.01 | |
| Gross profit | — | — | — | — | 0.19 | 0.25 | 0.29 | — | — | 0.53 | 0.56 | 0.53 | 1.67 | — | |
| Research & development | 0.05 | 0.08 | 0.12 | 0.12 | 0.12 | 0.17 | 0.26 | 0.48 | 0.54 | 0.65 | 0.67 | 0.53 | 0.46 | 0.43 | |
| Operating income | -0.05 | -0.10 | -0.17 | -0.13 | -0.06 | -0.12 | -0.24 | -0.43 | -0.37 | -0.45 | -0.44 | -0.30 | 0.87 | 0.13 | |
| Pre-tax income | -0.05 | -0.10 | -0.17 | -0.14 | -0.08 | -0.13 | -0.24 | -0.40 | -0.52 | -0.59 | -0.70 | -0.36 | 0.70 | -0.07 | |
| Income tax | — | -0.00 | 0.00 | 0.00 | 0.00 | -0.00 | 0.01 | 0.04 | 0.01 | -0.03 | -0.07 | 0.00 | 0.01 | -0.03 | |
| Net income | -0.05 | -0.09 | -0.17 | -0.14 | -0.08 | -0.13 | -0.25 | -0.44 | -0.52 | -0.56 | -0.63 | -0.36 | 0.68 | -0.04 | |
| Diluted EPS ($) | -5.18 | -2.97 | -5.07 | -4.17 | -2.02 | -2.75 | -4.27 | -6.64 | -7.43 | -7.79 | -8.37 | -4.73 | 7.78 | -0.58 | |
| Diluted shares (bn) | 0.013 | 0.032 | — | — | — | — | 0.059 | 0.066 | 0.070 | 0.072 | 0.075 | 0.077 | 0.088 | — |
USD billions · SEC XBRL
PTC Therapeutics, Inc. — questions
- What is PTC Therapeutics, Inc.'s revenue?
- $1.0B over the twelve months to 2026-06-30, down 42.8% year on year, from its 10-Q and 10-K filings.
- What is PTC Therapeutics, Inc.'s net income?
- -$38.4M over the twelve months to 2026-06-30.
- What is PTC Therapeutics, Inc.'s free cash flow?
- -$39.8M over the twelve months to 2026-06-30.
- What are PTC Therapeutics, Inc.'s diluted earnings per share?
- $-0.58 over the twelve months to 2026-06-30.
Every figure on this page comes from PTC Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.